MX2021009652A - Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. - Google Patents

Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.

Info

Publication number
MX2021009652A
MX2021009652A MX2021009652A MX2021009652A MX2021009652A MX 2021009652 A MX2021009652 A MX 2021009652A MX 2021009652 A MX2021009652 A MX 2021009652A MX 2021009652 A MX2021009652 A MX 2021009652A MX 2021009652 A MX2021009652 A MX 2021009652A
Authority
MX
Mexico
Prior art keywords
nicotinamide riboside
compositions
skin conditions
topical use
treating skin
Prior art date
Application number
MX2021009652A
Other languages
English (en)
Inventor
Ann Deren-Lewis
Troy Rhonemus
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of MX2021009652A publication Critical patent/MX2021009652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Abstract

Se proporcionan composiciones se contienen ribósido de nicotinamida (NR). Se utilizan composiciones que contienen NR para el cuidado o tratamiento de la piel y afecciones de la piel. En algunas realizaciones, la invención se refiere a composiciones farmacéuticas y composiciones cosméticas que contienen ribósido de nicotinamida. En realizaciones adicionales, la invención se refiere a métodos para utilizar ribósido de nicotinamida para promover el incremento de los niveles intracelulares del dinucleótido de nicotinamida y adenina (NAD+) en las células y los tejidos para mejorar la supervivencia de las células y los tejidos. Se proporciona un método para tratar las señales o síntomas del envejecimiento o arrugas de la piel en un individuo, que comprende administrar por vía tópica al individuo que necesite un tratamiento de este tipo una cantidad eficaz del compuesto ribosido de nicotinamida o sus sales.
MX2021009652A 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. MX2021009652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897713P 2013-10-30 2013-10-30
PCT/US2014/063260 WO2015066382A1 (en) 2013-10-30 2014-10-30 Nicotinamide riboside compositions for topical use in treating skin conditions

Publications (1)

Publication Number Publication Date
MX2021009652A true MX2021009652A (es) 2022-07-26

Family

ID=53005146

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009652A MX2021009652A (es) 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
MX2016005574A MX2016005574A (es) 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016005574A MX2016005574A (es) 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.

Country Status (12)

Country Link
US (2) US10688118B2 (es)
EP (1) EP3063163B1 (es)
JP (1) JP6509844B2 (es)
KR (3) KR20210107895A (es)
CN (2) CN109985056A (es)
AU (1) AU2014342185B2 (es)
CA (1) CA2928656C (es)
ES (1) ES2925879T3 (es)
MX (2) MX2021009652A (es)
NZ (1) NZ719328A (es)
WO (1) WO2015066382A1 (es)
ZA (1) ZA201603314B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170012449A (ko) 2014-06-02 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
ES2908332T3 (es) 2014-07-24 2022-04-28 Grace W R & Co Forma cristalina de cloruro de ribosilnicotinamida
AU2016229319B2 (en) 2015-03-09 2020-05-07 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
CN107531738B (zh) 2015-03-16 2021-02-19 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
JP6611099B2 (ja) * 2015-05-01 2019-11-27 ザ プロクター アンド ギャンブル カンパニー 皮膚の健康を改善する方法及びそのための組成物
WO2016178944A1 (en) 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
JP2018515485A (ja) 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善する方法及びニコチンアミドリボシドを使用したそのための組成物
US11426398B2 (en) * 2015-06-10 2022-08-30 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
WO2016210232A1 (en) * 2015-06-25 2016-12-29 N.V. Perricone Llc Niacinamide mononucleotide formulations for skin aging
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
WO2017004100A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Encapsulated particles comprising nicotinamide riboside
CN112315837B (zh) 2016-01-11 2021-12-03 宝洁公司 处理皮肤状况的方法以及用于其的组合物
US10000520B2 (en) 2016-03-16 2018-06-19 ChromaDex Inc. B-vitamin and amino acid conjugates ofnicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
US10183036B2 (en) 2016-04-20 2019-01-22 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors
WO2018039207A1 (en) * 2016-08-22 2018-03-01 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
CN110662542A (zh) 2016-11-11 2020-01-07 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成
CN110234238B (zh) 2016-11-29 2023-03-28 爱荷华大学研究基金会 Nad前体用于改善母体健康和/或后代健康的用途
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
CN110099672B (zh) 2016-12-21 2022-05-24 联合利华知识产权控股有限公司 具有氨基酸和烟酰胺化合物的局部皮肤增亮添加剂和组合物
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
EP3558246B1 (en) 2016-12-21 2021-10-20 Unilever IP Holdings B.V. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
CN110121331B (zh) 2016-12-21 2022-09-16 联合利华知识产权控股有限公司 含有难溶性化合物的个人护理组合物
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
CN111093676A (zh) * 2017-05-18 2020-05-01 益力舒健康公司 改善睡眠的方法和组合物
WO2018236814A2 (en) 2017-06-19 2018-12-27 Gangadhara Ganapati NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
JP6997222B2 (ja) 2017-06-23 2022-01-17 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するための組成物及び方法
WO2019023471A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING
KR20200053580A (ko) * 2017-09-14 2020-05-18 메구미 타나카 노화 방지제 및 노화 방지 방법
GB201716391D0 (en) * 2017-10-06 2017-11-22 Xobaderm Ltd Kit for delivery of an active compound into a biological barrier
WO2019126482A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
JP2021530447A (ja) 2018-07-03 2021-11-11 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company 皮膚状態の治療方法
JP6887025B2 (ja) * 2018-08-17 2021-06-16 邦泰生物工程（深▲セン▼）有限公司 安定型ニコチンアミドリボシド組成物及びその調製方法
KR102060374B1 (ko) * 2018-12-14 2019-12-30 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
MX2022000774A (es) * 2019-07-19 2022-05-03 Biosynth Ag Metodo para elaborar sales de ribofuranosido de nicotinamida, sales de ribofuranosido de nicotinamida como tal, y usos de las mismas.
CN110638827A (zh) * 2019-10-17 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh及其盐在制备皮肤色素抑制剂中的应用
KR102315139B1 (ko) 2019-12-17 2021-10-20 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
CN111184732B (zh) * 2020-03-04 2023-09-08 武汉华纳联合药业有限公司 一种复合组合物制剂及其制备方法和皮肤炎症中的应用
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
FR3110410A1 (fr) * 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
EP4153323A1 (fr) * 2020-05-20 2023-03-29 Nuvamid SA Compositions cosmetiques anti-age comprenant du nmn
EP4157206A1 (en) 2020-06-01 2023-04-05 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN111632049A (zh) * 2020-06-09 2020-09-08 西北农林科技大学 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方
US20230263817A1 (en) * 2020-08-28 2023-08-24 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN114933621A (zh) * 2022-04-13 2022-08-23 深圳市迪克曼生物科技有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007314A (es) * 2001-02-22 2003-12-04 Unilever Nv Composicion para la piel para reducir aceites y grasa de la piel.
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
JP2007521835A (ja) 2004-02-10 2007-08-09 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法
WO2006001982A2 (en) 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
JP2009500357A (ja) * 2005-07-07 2009-01-08 サートリス ファーマシューティカルズ， インコーポレイテッド 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物
EP3369738B1 (en) 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
US20100105638A1 (en) * 2007-03-12 2010-04-29 Kerstin Den-Braven Cosmetic compositions
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
JP5688376B2 (ja) * 2010-01-06 2015-03-25 株式会社ヤクルト本社 経口用のｄｎａ損傷修復促進剤及びエラスターゼ活性抑制剤

Also Published As

Publication number Publication date
AU2014342185B2 (en) 2019-01-03
US11033568B2 (en) 2021-06-15
US20200289536A1 (en) 2020-09-17
KR20220098049A (ko) 2022-07-08
US20160250241A1 (en) 2016-09-01
CA2928656C (en) 2020-07-28
CN109985056A (zh) 2019-07-09
EP3063163B1 (en) 2022-08-10
CA2928656A1 (en) 2015-05-07
WO2015066382A1 (en) 2015-05-07
ES2925879T3 (es) 2022-10-20
KR20160067195A (ko) 2016-06-13
ZA201603314B (en) 2017-09-27
JP2016538271A (ja) 2016-12-08
CN105873937A (zh) 2016-08-17
JP6509844B2 (ja) 2019-05-08
EP3063163A1 (en) 2016-09-07
NZ719328A (en) 2022-04-29
EP3063163A4 (en) 2017-05-10
US10688118B2 (en) 2020-06-23
KR20210107895A (ko) 2021-09-01
MX2016005574A (es) 2016-12-09

Similar Documents

Publication Publication Date Title
MX2021009652A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
MX2017011851A (es) Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
MX2018001363A (es) Derivados del mononucleotido de nicotinamida y sus usos.
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
AR093217A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
IN2015DN01616A (es)
MX2012006320A (es) Composiciones de amantadina y metodos para su uso.
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
NZ716033A (en) Treatment of papulopustular rosacea with ivermectin
MX2015012176A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
WO2012116990A3 (en) Novel use
MX2015013148A (es) Nuevos compuestos de bencensulfonamida, metodo para sintetizar los mismos, y uso de los mismos en medicina asi como tambien en cosmeticos.
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112012015984A2 (pt) composição para melhorar a função cerebral, e, polipeptídeo
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
TR201911076T4 (tr) Klorür içeriği azaltılmış fosfolipit içeren veya içermeyen hipotonik sulu bileşim.
NZ715905A (en) Compositions and methods for treating skin
UA116215C2 (uk) Спосіб лікування або полегшення плоского фолікулярного лишаю
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions